Richard Izewski, MD
Internal Medicine · Schaumburg, ILNPI 1306930177
Payments from drug & device makers
Across 276 payments — averaging $35.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$4K
- Novo Nordisk$1K
- Boehringer Ingelheim$881
- Johnson & Johnson$626
- Pfizer$590
- Amgen$327
- plus $2K from 29 others
What the payments were for
- Consulting fees$4,06441%
- Food & beverage$5,78158%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 1 | $4,064 |
| Novo Nordisk | 68 | $1,066 |
| Boehringer Ingelheim | 60 | $881 |
| Johnson & Johnson | 20 | $626 |
| Pfizer | 22 | $590 |
| Amgen | 12 | $327 |
| Novartis | 16 | $310 |
| Lilly USA, LLC | 16 | $309 |
| GSK | 4 | $188 |
| Merck | 4 | $187 |
| Exact Sciences | 7 | $167 |
| Bayer | 6 | $154 |
| Gilead | 2 | $145 |
| E.r. Squibb & Sons, L.L.C. | 7 | $133 |
| Melinta Therapeutics, LLC | 1 | $119 |
| AbbVie | 3 | $63 |
| Axsome Therapeutics, Inc. | 2 | $61 |
| Mannkind Corporation | 1 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| AstraZeneca | 3 | $49 |
| Lundbeck LLC | 3 | $47 |
| Abbott | 2 | $41 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Biogen | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| IBSA Pharma Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,904 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $112,795 |
| JardianceEmpagliflozin | 46 | $69,765 |
| TradjentaLinagliptin | 30 | $28,949 |
| XareltoRivaroxaban | 34 | $23,017 |
| JanuviaSitagliptin Phosphate | 17 | $17,417 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $16,709 |
| LinzessLinaclotide | 15 | $12,591 |
| MyrbetriqMirabegron | 15 | $10,386 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 167 | $6,847 |
| Novolog FlexpenInsulin Aspart | 13 | $4,056 |
| Diclofenac Sodium | 57 | $3,950 |
| Bumetanide | 23 | $2,857 |
| Atorvastatin Calcium | 303 | $2,850 |
| Gabapentin | 145 | $2,642 |
| Pantoprazole Sodium | 99 | $2,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $590 | $112,795142 claims |
| Boehringer IngelheimJardiance, Tradjenta | $881 | $98,71476 claims |
| Johnson & JohnsonXarelto | $626 | $23,01734 claims |
| MerckJanuvia | $187 | $17,41717 claims |
| AbbVieLinzess | $63 | $12,59115 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $10,38615 claims |
| Sanofi-aventis U.S. LLCLantus | $23 | $1,80219 claims |
| Lilly USA, LLCHumalog | $309 | $1,00911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Schaumburg
- Saifullah NasirSchaumburg$1.5M
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.